Latest Information Update: 17 Oct 2008
At a glance
- Originator Draco Lakemedel
- Class Antibronchitics; Expectorants
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bronchitis
Most Recent Events
- 17 Oct 2008 Removed MoA
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 08 Mar 1996 Discontinued-Clinical for Bronchitis in Sweden (Unknown route)